Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 7Active not recruiting 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 15NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Carcinoma, Non-Small-Cell Lung 298Neoplasms 179Breast Neoplasms 170Colorectal Neoplasms 107Neoplasm Metastasis 100Melanoma 99Multiple Myeloma 93Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 80Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 61Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 34Glioblastoma 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Smoldering Multiple Myeloma × Clear all
NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Active not recruiting
390 enrolled 12 charts 1 FDA
Plasma cell

Smoldering Multiple Myeloma

NCT05955508 2026-04-13

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
40 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡